QuickView for as601245 (compound)

1. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
3. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
4. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
5. L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens

1. Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene …
2. AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing C…
3. AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive de…
4. Breast Cancer Prognosis Prediction and Immune Pathway Molecular Analysis Based on Mitochondria-Relat…
5. Follistatin Is a Novel Chemoattractant for Migration and Invasion of Placental Trophoblasts of Mice.

There were no clinical trials for as601245